Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
Cancers · 30.06.2023 · 15 (13) · 3430
DOI: 10.3390/cancers15133430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.06.2023. Verfasst von Dirk Tomsitz und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University (LMU) Munich, 80337 Munich, Germany. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the German Federal Ministry of Education and Research (BMBF) as part of the project emed:MelAutim, German Federal Ministry of Education and Research (BMBF).
Abstract (Originalsprache)
Background
Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting. Patients and Methods: This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM.
Results
Patients treated with tebentafusp had a median PFS of 3 months (95% CI 2.7 to 3.3) and a median OS of 22 months (95% CI 10.6 to 33.4). In contrast to a published Phase 3 study, our cohort had a higher rate of patients with elevated LDH (65.4% vs. 35.7%) and included patients with prior systemic and local ablative therapies. In patients treated with tebentafusp following ICI, there was a trend for a longer median OS (28 months, 95% CI 26.9 to 29.1) compared to the inverse treatment sequence (24 months, 95% CI 13.0 to 35.0, p = 0.257). The most common treatment-related adverse events were cytokine release syndrome in 71.2% and skin toxicity in 53.8% of patients. Tumor lysis syndrome occurred in one patient.
Conclusions
Data from this real-life cohort showed a median PFS/OS similar to published Phase 3 trial data. Treatment with ICI followed by tebentafusp may result in longer PFS/OS compared to the inverse treatment sequence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University (LMU) Munich, 80337 Munich, Germany.
- Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
- Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany.
- Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
- Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland.
- Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
ORCID-Profile: Dirk Tomsitz, Markus Heppt, Ramon Staeger, Egle Ramelyte, Reinhard Dummer, Jens T Siveke, Cindy Franklin, Bastian Schilling
Förderung
- This work was supported by the German Federal Ministry of Education and Research (BMBF) as part of the project emed:MelAutim
- German Federal Ministry of Education and Research (BMBF)
Zitieren
APA
Tomsitz, D., Ruf, T., Heppt, M., Staeger, R., Ramelyte, E., Dummer, R., Garzarolli, M., Meier, F., Meier, E., Richly, H., Gromke, T., Siveke, J. T., Franklin, C., Klespe, K. C., Mauch, C., Kilian, T., Seegräber, M., Schilling, B., French, L. E., …, & Heinzerling, L. (2023). Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study. Cancers, 15(13), 3430. https://doi.org/10.3390/cancers15133430
Vancouver
Tomsitz D, Ruf T, Heppt M, Staeger R, Ramelyte E, Dummer R, et al. Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study. Cancers. 2023;15(13):3430. doi:10.3390/cancers15133430
BibTeX
@article{Tomsitz2023,
author = {Tomsitz, Dirk and Ruf, Theresa and Heppt, Markus and Staeger, Ramon and Ramelyte, Egle and Dummer, Reinhard and Garzarolli, Marlene and Meier, Friedegund and Meier, Eileen and Richly, Heike and Gromke, Tanja and Siveke, Jens T and Franklin, Cindy and Klespe, Kai-Christian and Mauch, Cornelia and Kilian, Teresa and Seegräber, Marlene and Schilling, Bastian and French, Lars E and Berking, Carola and Heinzerling, Lucie},
title = {Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study},
journal = {Cancers},
year = {2023},
volume = {15},
number = {13},
pages = {3430},
doi = {10.3390/cancers15133430}
}
EUVIMED